Catechol-O-Methyltransferase in Parkinson’s Disease

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer and colleagues in 1961 and Barbeau and colleagues in 1962, and in its ultimately successful form by Cotzias and colleagues in 1967, still represents the defining landmark in the treatment of PD (1-3). This dramatic advance was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.

Original languageEnglish (US)
Title of host publicationHandbook of Parkinson's Disease, Third Edition
PublisherCRC Press
Pages437-451
Number of pages15
ISBN (Electronic)9780203912164
ISBN (Print)9780824742423
StatePublished - Jan 1 2003
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Catechol-O-Methyltransferase in Parkinson’s Disease'. Together they form a unique fingerprint.

  • Cite this

    Pfeiffer, R. (2003). Catechol-O-Methyltransferase in Parkinson’s Disease. In Handbook of Parkinson's Disease, Third Edition (pp. 437-451). CRC Press.